Business
Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Corteva, Inc. announced that Nayaki Nayyar has been elected to Corteva’s Board of Directors, effective February 21, 2020.
Pawel Rosikiewicz - co-founder of “SwissAI Machine Learning Meetups” and of the SwissAI foundation - joins GenomSys in the role of Scientific Communications Expert.
Via a five-year collaborative research pact, Harvard and Guangzhou Institute will split $115 million in research funding provided by China Evergrande Group.
Katherine High, the longtime head of research and development at Spark Therapeutics, is stepping down from the company as it prepares to be absorbed by Swiss pharma giant Roche.
Agreement gives BIA Separations access to proprietary technology to better preserve integrity, infectivity and potency of immunoaffinity-purified viral vectors for gene therapy
“The good performance we saw in the third quarter has continued to further improve.
Namocell Inc. announced that it has entered into a collaboration with Takara Bio and HepaTx to use Namocell’s Single Cell Dispensers to perform single cell isolation on HepaTx’s unique hepatocyte-like cells developed from adipose tissue-derived stromal cells, and characterize them by single cell RNA-seq using Takara Bio’s SMART-Seq technology.
Biopharma and life sciences companies strengthen their leadership teams and board with this week’s Movers & Shakers.
Kazia Therapeutics is company focused on developing anti-cancer drugs.
Immatics is eligible for more than $550 million in various commercial milestone payments for each product as well as additional royalties.